Introduction
Gene therapy has become an attractive concept for a broad variety of biomedical applications. The potential of gene therapy for directing the expression of therapeutic genes to the target cells makes it particularly attractive for treatment of cancer. In theory, multiple levels of target specificity are attainable by exploiting specific delivery mechanisms to target the tumor (biochemical or physical targeting), [1] [2] [3] [4] specific intracellular characteristics of the target cells (eg preferential targeting of proliferating cells), 5 controlled tissue-specific expression (transcriptional targeting), 6 and utilizing biological amplification mechanisms (eg during transcription/ translation, bystander effects, triggering immune effector mechanism). However, the lack of effective and targetspecific vectors is a major bottleneck for somatic gene therapy to date. Efficient and target-specific gene delivery in vivo has to overcome a variety of intracellular barriers, including uptake into the target cells, release from the endosomal compartment, nuclear uptake, as well as extracellular barriers, such as anatomical size constraints and protection from non-specific interactions with biological fluids and non-target cells.
Recently we have developed surface-shielded transferrin-polyethylenimine (Tf-PEI)-based gene delivery systems that are able to target gene expression to distant tumors after systemic application in murine models. 7, 8 In the present study we have employed these gene delivery systems to target gene expression of a highly potent, yet highly toxic molecule, tumor necrosis factor (TNF␣), to distant tumors with the aim to separate the antitumor activity of TNF␣ from its systemic toxicity.
Surface-shielded ligand-polycation/DNA complexes for tumor-targeted gene delivery
Condensation of DNA by electrostatic interactions with polycations is being used to protect DNA from degradation by nucleases, resulting in formation of compact particles that can be taken up by the cells. Among the synthetic vectors, polyethylenimine (PEI) shows particularly promising efficacy in transfection in cell culture, as well as in a variety of applications in vivo. 9, 10 Beside its DNA condensing activity PEI has an intrinsic endosomolytic activity mediating the escape of DNA from the endosomal department by a 'proton sponge' mechanism. 9, 11 To combine the high gene transfer efficacy of PEI/DNA complexes with the target-specific mechanism of receptor-mediated uptake, we have incorporated the cell-binding ligand transferrin (Tf) into the complex by chemical coupling to PEI. 2 Binding of the Tf ligand-containing DNA complexes to the Tf receptor, which is overexpressed on a variety of tumor cells, 1 was shown to greatly enhance uptake of DNA complexes into the cells, resulting in efficient transfection in a broad variety of cell lines and primary cell cultures. 1, 2 However, compared with cell culture applications, gene delivery in vivo has to overcome additional barriers. Passing blood circulation and organs such as liver and spleen, which are specialized in removal of foreign particles, poses obstacles particularly for systemic application of transfection complexes. Another major problem are nonspecific interactions with blood components, extracellular matrix and non-target cells. Positively charged polycation/DNA complexes were found to aggregate at physiological salt concentrations, to interact with components of the coagulation and complement systems, and to cause aggregation of erythrocytes which can result in the occlusion of capillaries, eg in the lungs, leading to lung embolism. [12] [13] [14] Furthermore, recognition and uptake of complexes by cells of the reticuloendothelial system will cause rapid removal from the circulation.
We have shown that nonspecific interactions with plasma components or erythrocytes can be prevented by shielding the surface of transfection particles by covalent modification with polyethylene glycol (PEG) without affecting the target-specific transferrin ligand-receptor interactions. 7, 12 Recently an alternative strategy for masking the surface charge of DNA complexes was developed, by incorporating Tf at high densities into the complex which shielded the positive surface charge of PEI/DNA complexes, in the absence of PEGylation 8 ( Figure 1a ). Furthermore, shielding of the surface charge of PEI/DNA complexes, generating particles with a near neutral zetapotential, blocked non-specific interaction, eg with erythrocytes. In contrast, non-shielded complexes induce massive erythrocyte aggregation (Figure 1c Systemic application of non-shielded luciferase reporter gene complexes into tumor-bearing mice resulted in high gene expression in the lungs, and lower gene expression in other organs, such as the heart and liver, but was often accompanied by considerable toxicity (Figure 2a) . Particularly when high molecular PEI800/DNA complexes were used approximately half of the animals died with signs of lung embolism. 7 Complexes using low molecular weight PEIs (eg 25 kDa or 22 kDa) showed generally lower toxicity. 8, 10, 15 However, with all PEIs lung expression was prominent with varying expression levels in other major organs or the tumor. In contrast, Tf-PEI/DNA complexes shielded either by PEG or high density Tf resulted in preferable reporter gene expression in the tumor. Furthermore, expression in the lungs or in the other organs is dramatically reduced (Figure 2b, c) . Shielding of the transfection complexes from nonspecific interactions was shown to lead to longer circulation times in the blood, 12 resulting in extravasation in areas of higher vascular permeability such as tumors ('passive targeting'). 14, 16, 17 Studies on the biodistribution of transfection complexes confirmed a significant accumulation of shielded transfection complexes in the tumor compared with non-shielded complexes. 7, 8 Beside the passive targeting, obviously active targeting mechanisms, such as enhanced uptake by Tf-receptor expressing 1,2 and highly proliferating tumor cells 5 contribute to the preferential gene expression in the tumor. 
Figure 2 Luciferase reporter gene expression after systemic gene delivery into tumor-bearing mice. Positively charged PEI/DNA (containing 50 g DNA, pCMVL) complexes (a), or surface-shielded Tf-PEI/DNA complexes after PEGylation (b) or high density transferrin incorporation (c) were injected into the tail vein of A/J mice (250 l/mouse) bearing subcutaneously growing Neuro2a tumors. Gene expression in the major organs and tumor 24 h after application was measured by luciferase assay. Transfection efficacy is expressed as RLU (relative light units

Tumor-targeted gene delivery of TNF␣
We were interested in applying this tumor-targeted gene delivery system for delivering a highly active effector molecule, tumor necrosis factor-␣ (TNF␣), a cytokine with pronounced antitumor activity.
18 TNF␣ acts on a broad variety of cells, particularly damaging the vascular system of the tumor. The problem with conventional TNF␣ protein therapy has been its high systemic toxicity. 19 Since both antitumor activity and systemic toxicity
Gene Therapy seem to share common pathophysiological mechanisms, the only possibility to separate the antitumor activity from its systemic toxicity is to localize TNF␣ activity to the tumor. 20 Surface-shielded transfection complexes containing an expression plasmid coding for murine TNF␣, applied systemically via the tail vein of A/J mice bearing subcutaneously growing Neuro2a tumors in their flank, resulted in significant TNF␣ gene expression within the tumor, without detectable serum levels (Figure 3a) . Repeated application of surface-shielded TNF␣ coding complexes into Neuro2a tumor-bearing mice induced in the majority of the animals a pronounced hemorrhagic tumor necrosis, which is one of the hallmarks of the antitumor activity of TNF␣. Moreover, hemorrhagic necrosis was focused specifically to the tumor, and no systemic toxicity was observed. After 1 week of treatment 85% of the TNF␣-treated animals developed hemorrhagic tumor necrosis. In comparison, without treatment or after application of similar transfection complexes containing either the ␤-galactosidase reporter gene or the non-expressing pSP65 plasmid a limited tumor necrosis was observed in 5%, 16% or 12% of the animals, respectively. Induction of hemorrhagic tumor necrosis resulted in a significant inhibition of tumor growth in the TNF␣-treated animals as compared with the control groups (Figure 3b) .
In a second tumor model, the MethA fibrosarcoma model growing subcutaneously in BALB/c mice, surfaceshielded TNF␣ complexes similarly induced pronounced hemorrhagic tumor necrosis (Figure 3c compared with  d) . Furthermore, no systemic TNF-related toxicity was observed after repeated applications. In this model, 60% of the TNF␣-treated animals finally developed complete tumor regression (Figure 3e ). These animals were also protected from subsequent MethA tumor rechallenge. In contrast, in untreated animals or control animals, which received similar transfection complexes containing the ␤-galactosidase gene, no hemorrhagic necrosis and only occasionally spontaneous tumor regressions were observed.
Conclusions
Controlled delivery of therapeutic effector molecules by targeted gene expression in the desired target tissues is a major potential of gene therapy for the treatment of cancer. The focus of the present study was to target the activity of a highly active, yet highly toxic effector molecule, such as TNF␣, to distant tumors following systemic application using targeted delivery of the TNF␣ gene. A surface-shielded transferrin-polyethyleniminebased gene delivery system was employed as the technological platform to target gene expression to distant tumors. In this system, DNA is shielded from non-specific interactions with plasma proteins and non-target cells, resulting in prolonged blood circulation and passive extravasation in areas of increased vascular leakiness, such as tumors. Furthermore, ligands such as transferrin, give the possibility of active targeting to the respective receptor on the tumor cells.
Targeting TNF␣ activity using surface-shielded gene delivery systems resulted in significant TNF␣ gene expression in the tumor without detectable serum levels. In contrast non-shielded complexes resulted in an unspecific TNF␣ expression pattern and significant TNF␣ serum levels associated with significant body weight loss (data not shown). Targeted TNF␣ complexes induced hemorrhagic tumor necrosis and inhibition of tumor growth in tumor models of different tissue origin such as neuroblastoma, fibrosarcoma, and melanoma (Kircheis et al, manuscript submitted). Using this technology platform we have focused TNF␣ gene expression on the tumor, leading to therapeutic effects, whilst reducing systemic toxicity which is associated with systemic TNF␣ protein therapy. Furthermore, this technology has the potential to target multiple metastatic nodules disseminated throughout the body. In summary, targeted gene delivery to tumors may be an attractive strategy applicable to TNF␣ and other highly active, yet toxic, molecules in the treatment of inoperable and metastatic cancer disease.
